BioTech IP Review

Combination of Vanzacaftor, Tezacaftor, Deutivacaftor for Treating Cystic Fibrosis

  • Applicant: Vertex Pharmaceuticals Incorporated
  • Patent Application (PCT): PCT/US2025/014303
  • Title: Combination of Vanzacaftor, Tezacaftor, Deutivacaftor for Use in Treating Cystic Fibrosis
  • Filing Date: February 3, 2025
  • Publication Number: WO/2025/166342
  • Publication Date: August 7, 2025
  • Inventors: Bartlomiej Borek, Carmen Bozic, Weichao George Chen, et al.

What It Covers

This international patent application covers specific combination therapy compositions and associated methods for the treatment of cystic fibrosis (CF) using three small-molecule CFTR modulators:

  • Vanzacaftor, Tezacaftor, and Deutivacaftor:
    These are modulators of the CFTR (cystic fibrosis transmembrane conductance regulator) protein — compounds designed to improve the folding, trafficking, and channel function of mutant CFTR proteins that cause CF.
  • Combination Therapy Regimen:
    The patent claims the specific combination of these three CFTR modulators in coordinated therapeutic formulations and dosing regimens designed to maximize clinical benefit (e.g., improved lung function, reduced pulmonary exacerbations) across a wide range of CF genotypes.
  • Pharmaceutical Compositions:
    It includes claims covering how to formulate these compounds — alone or together — into dosage forms (e.g., tablets) that can be safely administered to CF patients.

Why It’s Important

1. Protects Next-Generation CF Therapy

Vertex’s CF franchise — led historically by Trikafta and its successors — generates multi-billion-dollar annual revenue. Competitors are eager to enter the space once existing patents expire. This patent extends exclusivity on future CF combination therapies, supporting long-term commercial value.

2. Strengthens Market Position Ahead of Patent Expirations

With earlier Trikafta patents set to expire in the latter 2030s, strategic patenting on new combinations (e.g., involving vanzacaftor and deutivacaftor) helps Vertex protect its market share — especially important as other modulators and generics emerge.

3. Broad Patient Coverage

By claiming combinations effective for a wide range of CFTR mutations, the patent supports treatments for a broader CF patient population, which increases the potential addressable market and justifies premium pricing and long-term uptake globally.

4. Strategic R&D Signal

Filing this patent reinforces that Vertex continues R&D investment in CFTR small-molecule therapies, not just in biologics (e.g., cell therapies) or pain management drugs, ensuring a diversified and resilient product pipeline.

Summary

PCT/US2025/014303 — “Combination of Vanzacaftor, Tezacaftor, Deutivacaftor for Use in Treating Cystic Fibrosis”, filed February 3, 2025 and published August 7, 2025, is one of Vertex’s most strategically important patent filings. It secures intellectual property around next-generation CFTR modulator combinations — a key foundation for sustaining revenue from cystic fibrosis therapies in the years after current blockbusters face competitive pressures.

Leave a comment